

# Florian Slimano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/66870/publications.pdf>

Version: 2024-02-01

29  
papers

226  
citations

1306789

7  
h-index

1125271

13  
g-index

35  
all docs

35  
docs citations

35  
times ranked

386  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2400. | 1.0 | 42        |
| 2  | Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines). <i>Cancer Treatment Reviews</i> , 2020, 88, 102063.                                      | 3.4 | 30        |
| 3  | Predictive factors for clinically significant pharmacist interventions at hospital admission. <i>Medicine (United States)</i> , 2018, 97, e9865.  | 0.4 | 27        |
| 4  | Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients. <i>BMC Cancer</i> , 2018, 18, 955.   | 1.1 | 21        |
| 5  | Pharmacists'™ interventions on prescription problems in one French community pharmacy: A prospective pilot study. <i>Annales Pharmaceutiques Francaises</i> , 2018, 76, 299-305.  | 0.4 | 9         |
| 6  | Impact of Pharmacists-Led Interventions in Primary Care for Adults with Type 2 Diabetes on HbA1c Levels: A Systematic Review and Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3156.      | 1.2 | 8         |
| 7  | Computerized pediatric oncology prescriptions review by pharmacist: A descriptive analysis and associated risk factors. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26897.   | 0.8 | 7         |
| 8  | Providing Oncology Pharmacy Services During the Coronavirus Pandemic: French Society for Oncology Pharmacy (Soci t  Francaise de Pharmacie Oncologique [SFPO]) Guidelines. <i>JCO Oncology Practice</i> , 2020, 16, e1282-e1290.                | 1.4 | 6         |
| 9  | The Role of Community Pharmacists in the Detection of Clinically Relevant Drug-Related Problems in Chronic Kidney Disease Patients. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 89.   | 0.6 | 6         |
| 10 | Is antihistaminergic H2 really useful in prevention of hypersensitivity induced by paclitaxel?. <i>Supportive Care in Cancer</i> , 2016, 24, 4475-4477.   | 1.0 | 5         |
| 11 | Capecitabine and adermatoglyphia: trouble in border!. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e283-e284.  | 1.3 | 5         |
| 12 | Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 1265-1271.   | 1.0 | 5         |
| 13 | Nightmares and hallucinations with aprepitant and opium powder: a suspected drug drug interaction. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 454-456.   | 1.1 | 5         |
| 14 | Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France. <i>Supportive Care in Cancer</i> , 2019, 27, 3179-3182.  | 1.0 | 4         |
| 15 | Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study. <i>Lung Cancer</i> , 2022, 166, 114-121.                                 | 0.9 | 4         |
| 16 | Development of a  ready-to-use ™ tool that includes preventability, for the assessment of adverse drug events in oncology. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 376-385.   | 1.0 | 3         |
| 17 | Intratumoral distribution of YSNSC cyclopeptide in a mouse melanoma model using microdialysis. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 143, 105201.  | 1.9 | 3         |
| 18 | Organization of chemotherapeutic preparations in advance: Do we save or waste money?. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1699-1703.   | 0.5 | 3         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Development and validation of a ready-to-use score to prioritise medication reconciliation at patient admission in an orthopaedic and trauma department. <i>European Journal of Hospital Pharmacy</i> , 2022, 29, 264-270.  | 0.5 | 3         |
| 20 | Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients' Profiles With Oxaliplatin-Induced Peripheral Neuropathy. <i>Frontiers in Pharmacology</i> , 2021, 12, 744085. | 1.6 | 3         |
| 21 | One-year COVID-19 outcomes on the oncology care patient pathway: Results of a French descriptive, cross-sectional comprehensive study (ONCOCARE-COV). <i>Cancer Medicine</i> , 2022, 11, 4865-4879.   | 1.3 | 3         |
| 22 | First plasma and tissue pharmacokinetic study of the YSNSG cyclopeptide, a new integrin antagonist, using microdialysis. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 105, 178-187.   | 1.9 | 2         |
| 23 | Economical simulations for the optimal use of anti-programmed cell death-1 in advanced melanoma patients: Report of a budget impact analysis. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1216-1219.   | 0.5 | 2         |
| 24 | A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 107815522110279.   | 0.5 | 1         |
| 25 | Safety and Survival Outcomes in Lung Cancer Patients Receiving Carboplatin: Impact of Uncapped Dosage. <i>Chemotherapy</i> , 2021, 66, 72-77.   | 0.8 | 1         |
| 26 | Clinical and Organizational Impacts of Medical Ordering Settings on Patient Pathway and Community Pharmacy Dispensing Process: The Prospective ORDHOSPIVILLE Study. <i>Pharmacy (Basel, Switzerland)</i> , 2022, 10, 2.   | 0.6 | 1         |
| 27 | GRP-072...Exposure to Antineoplastic Agents in Oncology Departments: Practise Survey and Information to the Personnel of Three Oncology Departments. <i>European Journal of Hospital Pharmacy</i> , 2013, 20, A26.2-A26.  | 0.5 | 0         |
| 28 | OHP-006...Adverse Effects of Day-Hospital Cancer Treatment Monitored at Home: Creation of a Physician-patient Logbook. <i>European Journal of Hospital Pharmacy</i> , 2013, 20, A137.3-A138.  | 0.5 | 0         |
| 29 | Aprepitant for paediatric chemotherapy-induced nausea and vomiting. <i>Lancet Oncology</i> , The, 2015, 16, e259.   | 5.1 | 0         |